Comparison between a liquid chromatography‐tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations
Authors:
- 11 July 2008
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 22 (4) , 282-285
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Crossreactivity of Isolated Everolimus Metabolites With the Innofluor Certican Immunoassay for Therapeutic Drug Monitoring of EverolimusTherapeutic Drug Monitoring, 2007
- Internal Standard Selection for the High-Performance Liquid Chromatography Tandem Mass Spectroscopy Assay of Everolimus in BloodTherapeutic Drug Monitoring, 2007
- Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantationClinica Chimica Acta, 2007
- Internal Standard Selection for Immunosuppressant Drugs Measured by High-Performance Liquid Chromatography Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2007
- Comparison of the Innofluor® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantationClinical Biochemistry, 2006
- The Role of Therapeutic Drug Monitoring in Individualizing Immunosuppressive Drug Therapy: Recent DevelopmentsTherapeutic Drug Monitoring, 2006
- Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipientsClinical Biochemistry, 2006
- EverolimusDrugs, 2006
- Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction–high performance liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2004